Our research is focused on identification of optimal compositions of cannabis-derived molecules to treat different medical indications.

The development of high standard cannabis-based products for specific medical indications is of high priority.

Cannabis sativa contains more than 600 different secondary metabolites, including phytocannabinoids and terpenoids, present in different ratios and compositions in multiple diverse strains grown around the world. Yet, the specific beneficial molecules for medical use remain elusive.

In an effort to identify cannabis compounds with biological activities associated with medical indications, we established deep chemical analysis capabilities, and a variety of in vitro and ex vivo biassays. These allow on the one hand identification of cannabis molecules (API) and their synergistic combinations with specific biological activity, on the other- insight into the mode of action of these API.  These API serve as a base for new cannabis-based drug development.

For each of the synergistic API, for each medical indication, we examine networks of gene expression, protein localization, and cell cytoskeleton modification, to establish API mode of action and targets.  A major advantage of this development is the ability to specify cannabis activity at the molecular level, as effectors of specific pathways. Interestingly, some of these pathways are target for other chemical drugs develop for treatment of the certain medical indication.